Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD)
with unknown etiology in which gradual fibrotic scarring of the lungs leads to usual interstitial …

Since the initial identification of the novel coronavirus SARS-CoV-2 in December 2019, the
COVID-19 pandemic has become a leading cause of morbidity and mortality worldwide. As …

Alveolar epithelium plays a pivotal role in protecting the lungs from inhaled infectious
agents. Therefore, the regenerative capacity of the alveolar epithelium is critical for recovery …

Idiopathic pulmonary fibrosis (IPF) is a fatal disease in which the intricate alveolar network of
the lung is progressively replaced by fibrotic scars. Myofibroblasts are the effector cells that …

Fibrotic diseases occur in a variety of organs and lead to continuous organ injury, function
decline, and even failure. Currently effective treatment options are limited. Galectin-3 (Gal-3) …

Transforming growth factor (TGF)-β1, a main profibrogenic cytokine in the progression of
idiopathic pulmonary fibrosis (IPF), induces differentiation of pulmonary fibroblasts to …

Fibrosis is a common pathological sequela of tissue injury or inflammation, and is a major
cause of organ failure. Subsets of fibroblasts contribute to tissue fibrosis in multiple ways …

Biomarkers have the potential to become central to the clinical evaluation and monitoring of
patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype …

Radiation therapy is one of the most common treatment strategies for thorax malignancies.
One of the considerable limitations of this therapy is its toxicity to normal tissue. The lung is …

Radiation-induced lung injury (RILI), including acute radiation pneumonitis and chronic
radiation-induced lung fibrosis, is the most common side effect of radiation therapy. RILI is a …